Pre-Award Synopsis Texas Shield

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DEF ADVANCED RESEARCH PROJECTS AGCY

Contract Value

Not provided

Codes & Classification
Solicitation Number

DARPA-SN-27-07

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Classification Code

AC12

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
Documents2
The Defense Advanced Research Projects Agency (DARPA), operating under the Department of Defense, has issued a Special Notice (Procurement Identifier: DARPA-SN-27-07) regarding its intent to enter into an agreement with The University of Texas System consortium of universities. This initiative is being conducted in support of DARPA’s Biological Technologies Office (BTO) and is associated with the LiveChain Program. The primary focus of this integrated research effort is to advance capabilities in autonomous medical care, casualty evacuation, clinical decision support, and the development of resilient medical supply chains, particularly for application in austere and contested environments. This notice is strictly informational and does not constitute a request for proposals or a competitive solicitation. Instead, it serves as a pre-award synopsis to inform the public of DARPA’s intention to collaborate with the specified academic consortium. The scope of the anticipated agreement encompasses research and development activities aimed at enhancing medical response and support systems in challenging operational contexts, leveraging biotechnology solutions to address critical gaps in autonomous and resilient healthcare delivery. The procurement is classified under NAICS Code 541714, which pertains to Research and Development in Biotechnology (except Nanobiotechnology), as per the 2022 NAICS version. The associated Product Service Code is AC12, further indicating a focus on research and development in the life sciences domain. The contracting entity for this opportunity is the Defense Advanced Research Projects Agency (DARPA), specifically through its Biological Technologies Office, with Dr. Jennifer Mindock serving as the primary point of contact. Interested parties may direct inquiries to [email protected]. As a Special Notice, this procurement activity is not open for competitive bidding, and there are no set-aside requirements or solicitation documents associated with this announcement. The notice is currently active, with a post date of October 16, 2026, and a response date of November 15, 2026, though the response mechanism is limited given the non-competitive nature of the notice. Contractors evaluating this opportunity should note that the engagement is intended to foster advanced research collaborations in biotechnology, with a particular emphasis on medical autonomy and resilience in operationally demanding settings. The partnership with The University of Texas System consortium underscores DARPA’s commitment to leveraging academic expertise to address complex defense-related medical challenges. The core elements of the initiative—autonomous care, casualty evacuation, decision support, and supply chain resilience—are expected to remain central throughout the contract lifecycle. For further details and official documentation, interested parties are encouraged to consult the notice on SAM.gov using Opportunity ID 7b49663d4b6b4153972c570936240e59.